10x Genomics Inc

Financials

Total assets 937.79 M918.64 M903.39 M979.97 M1.03 B1.04 B Total liabilities 214.99 M208.5 M196.5 M206.69 M242.24 M245.04 M Total equity 722.8 M710.13 M706.89 M773.28 M785.12 M796.33 M Total liabilities & shareholders' equities 937.79 M918.64 M903.39 M979.97 M1.03 B1.04 B Total debt —————— Net debt ——————

10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics.

TXG

Financials

10x Genomics Inc

Noticias

Canada stocks higher at close of trade; S&P/TSX Composite up 0.61%

Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?

Priceline, Carvana, DoorDash and more set to report earnings Wednesday

10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript

Obiettivo di prezzo per le azioni di 10X Genomics alzato a $22 da $20 da Canaccord Genuity

10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity

Applied Materials and Rivian among market cap stock movers on Friday

Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics

10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates

10X Genomics affronta la prova degli utili con il debutto della nuova strategia di prezzi

10X Genomics faces earnings test as new pricing strategy debuts

Canada stocks higher at close of trade; S&P/TSX Composite up 0.71%